• 医学文献
  • 知识库
  • 评价分析
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
  • 临床诊疗知识库
  • 中医药知识库
  • 机构
  • 作者
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

医学文献>>
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
热搜词:
换一批

糖皮质激素性骨质疏松致病机制最新研究进展

Recent advances in the glucocorticoid-induced osteoporosis

摘要Glucocorticoid is widely used in anti-inlfammatory and immune-modulatory drugs while its related side effects shouldn’t allow to be neglected, such as osteoporosis, diabetes, and obesity. Clinical applications of it has also been greatly restricted. Improvement of results of these unnecessary outcomes also become the main challenge of medical work. To explore the pathogenetic mechanisms of glucocorticoid-induced osteoporosis ( GIO ) and its effects on bone and mineral metabolism are of crucial importance. Endogenous glucocorticoid of physiological-concentration is not only a key regulating factor for differentiation of mesenchymal stem cells and bone development, but also involved in regulating calcium handling by kidney and gastrointestinal tract. As supra-physiological concentration, it acts as a “double-edged sword” role, taking unfavorable effect in the same tissue. Over the years there has been a controversial paradox about GIO mechanism for the anabolic and catabolism of glucocorticoid, which needs to be further in-depth studied. This paper reviews highlighted recent advances on physiology and pathology of glucocorticoid for bone metabolism, and to provide new strategies for prophylaxis and treatment of GIO.

更多
广告
  • 浏览294
  • 下载206
中国骨与关节杂志

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷